Treatment of cancer-associated hemolytic uremic syndrome with staphylococcal protein A immunoperfusion.
Plasma perfusion over filters containing staphylococcal protein A (SPA) was used to treat 11 patients with adenocarcinoma who developed a hemolytic uremic syndrome. Immunoperfusion resulted in complete clearance of pretreatment elevated levels of circulating immune complexes in eight of the 11 patients with normalization of complement values depressed at the start of the therapy in seven. A significant rise in platelets and erythrocyte counts was achieved in nine patients, and stabilization of progressive renal impairment was achieved in six. The response was incomplete and short lived in three patients with clinically evident tumor recurrence, whereas long-term control of the syndrome was demonstrated in seven patients in complete tumor remission (no recurrence with median follow-up of 9 months). SPA immunoperfusion appears to be an effective form of therapy for this otherwise fatal syndrome.
D000230:Adenocarcinoma / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D000368:Aged; D000936:Antigen-Antibody Complex / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001769:Blood; D003176:Complement C3 / Q000032:analysis; D003181:Complement C4 / Q000032:analysis; D005260:Female; D005500:Follow-Up Studies; D006463:Hemolytic-Uremic Syndrome / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013205:Staphylococcal Protein A / Q000627:therapeutic use*; D014462:Ultrafiltration
D000936:Antigen-Antibody Complex; D003176:Complement C3; D003181:Complement C4; D013205:Staphylococcal Protein A